Related Experiment Video
Updated: Jun 2, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[Current treatment of hepatitis B infection: where do the new nucleos(t)ide analogues fit in?]
Javier Fuentes Olmo1, Rafael Uribarrena Amézaga
1Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet, Zaragoza, España. jfuentesolmo@sepd.es
Abstract:
One of the most important advances made in the treatment of chronic hepatitis B infection has been the development of nucleos(t)ide analogues. The first antiviral agents used had limited efficacy due to the high resistance rate. However, in the last few years, new agents (tenofovir, entecavir) have been developed with greater antiviral potency and a lower resistance rate. Consequently, these agents are considered to be the treatment of choice in the most recent clinical guidelines. Nevertheless, interferon may still play an important role in the treatment of hepatitis B in selected patients. Moreover, in some contexts, such as renal insufficiency, pregnancy or immunosuppression, the role of the new oral antiviral agents has not been precisely defined. The present review analyzes these aspects, as well as some of the particular features of the management of patients treated with nucleos(t)ide analogues.
More Related Videos
Related Concept Videos
Antiviral Nucleoside Inhibitors
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Inhibitors Of Virion Release

